CanDeal Data & Analytics Named Best Buy-Side Evaluated Pricing Service for Second Year in a Row
November 1, 2024 – Toronto – CanDeal DNA is honored to announce that our Reference Pricing Service has been named the 2024 Best Buy-Side Evaluated Pricing Service for the second year in a row in the WatersTechnology annual Buy-Side Technology Awards. The program recognizes the leading technologies and innovation addressing the buy side's most pressing business, regulatory, operational and technology needs.
CanDeal DNA Reference Pricing Service uses unique data sources, governance, domestic market conventions and proprietary methodologies to publish accurate, intraday pricing, analytics and security master data for nearly 100,000 Canadian fixed income securities, and rates for OIS/swaps. We help buy-side participants who previously struggled to value fixed-income holdings with accuracy and fidelity to the traded market, which increased risk, and changed how they access, analyze and create strategies for Canadian fixed income and IRD markets.
“CanDeal DNA products provide participants enhanced tools to compete on the global stage and attract more advanced investor insights and trading models,” said Andre Craig, President, CanDeal DNA. “We’ve positioned ourselves centrally in a market structure evolution and are changing the way firms are engaging in OTC data sets to manage risk, gain insights and overall obtain access to this data with a seamless suite of solutions that were previously unattainable for Canadian fixed income markets.”
Available via FTSE Russell, Fundata, ICE, LSEG, S&P Global and SS&C, buy-side participants active in the Canadian fixed income market gain access to unparalleled coverage for all Canadian money market and bond types, supported by a transparent, detailed price challenge process.
“Our partnership with CanDeal DNA has enabled us to bring more accurate pricing for the Canadian bond market in a constantly evolving and innovative environment for our clients,” said Paul Bowes, Country Head at FTSE Russell. “CanDeal DNA has been leading the charge in driving best-in-class OTC pricing and analytics solutions and we have been delighted to have such a positive and collaborative relationship to the benefit of our client base.”